Journal of Blood Medicine (Oct 2019)
Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes
Abstract
Danielle Cuthbert,1 Brady Lee Stein2 1McGaw Medical Center of Northwestern University, Department of Internal Medicine, Chicago, IL 60611, USA; 2Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology, Department of Medicine, Chicago, IL 60611, USACorrespondence: Brady Lee SteinNorthwestern University Feinberg School of Medicine, Division of Hematology/Oncology, Department of Medicine, 645 N. Michigan Avenue, Suite 1020, Chicago, IL 60611, USATel +1 312 695 6832Fax +1 312 695 7814Email [email protected]: Polycythemia vera is a Philadelphia-negative chronic myeloproliferative neoplasm, characterized by erythrocytosis, which is unique, compared to essential thrombocytosis and primary myelofibrosis. Though longevity can usually be expected, vascular morbidity is associated with this condition, as well as a propensity to evolve into myelofibrosis (post-PV MF) and acute myeloid leukemia. In addition, patients can have a pronounced symptom burden. Herein, contributors to the symptomatic burden, as well as the thrombotic and transformative tendencies are reviewed. From a symptom perspective, some are explained by cytokine release, others by microvascular complications, whereas certain symptoms can herald disease evolution. Thrombosis has multifactorial contributors, including but not limited to gender, and inflammatory stress; investigators have recently hypothesized that microparticles and Neutrophil Extracellular Trap Formations may add to thrombotic burden. Finally, we examine the progression to post-PV MF as well as leukemic transformation, highlighting well-established risk factors including age and leukocytosis, certain treatments, and the presence of “non-driver” mutations.Keywords: polycythemia vera, symptomatic burden, thrombosis, myelofibrosis, leukemic transformation
